查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1974310

mRNA合成与製造市场：依服务、服务类型、製造流程、製造规模、技术、应用、使用方法及最终用户划分－2026-2032年全球预测

mRNA Synthesis & Manufacturing Market by Services, Service Type, Manufacturing Process, Manufacturing Scale, Technology, Application, Usage, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，mRNA 合成和製造市场价值将达到 29.6 亿美元，到 2026 年将成长到 32.3 亿美元，到 2032 年将达到 56.7 亿美元，复合年增长率为 9.71%。

主要市场统计数据
基准年 2025 29.6亿美元
预计年份：2026年 32.3亿美元
预测年份 2032 56.7亿美元
复合年增长率 (%) 9.71%

作为权威的 mRNA 合成与生产入门教材，说明了科学基础、商业化途径、监管发展以及供应链的复杂性。

传讯RNA的合成与生产融合了分子生物学、工程学、监管科学和全球供应链管理等多个学科，共同致力于开发新型治疗方法和疫苗平台。其核心科学在于mRNA生产工艺，该工艺透过一系列特定步骤，例如模板DNA製备、体外转录、加帽加尾、多聚腺苷酸化、纯化和製剂化，将数位化基因设计转化为化学和结构优化的RNA构建体。每个步骤都需要专门的试剂、设备和製程控制，这体现了RNA分子的精细结构以及确保产品品质对人类和动物使用至关重要的必要性。

定义变革性转变，这将重塑 mRNA 的合成和生产，其驱动力包括平台技术、递送方法创新、监管进步和策略伙伴关係。

由于技术成熟、策略联盟的建立以及监管要求的改变，mRNA合成和生产领域正经历变革时期。脂质奈米颗粒设计和新型递送方式的进步，正在拓展mRNA疗法的应用范围，使其超越传统疫苗，实现更精准的标靶递送并提高耐受性。同时，酵素加帽化学、加帽类似物和多聚腺苷酸化技术的改进，正在提升转录物的稳定性和翻译效率，进而提高mRNA构建体的治疗指数。

检验美国于 2025 年实施的关税对 mRNA 合成供应链、筹资策略、成本结构和竞争地位的累积影响。

美国2025年实施的关税政策调整对整个mRNA合成价值链产生了多方面的影响，包括采购、成本结构和策略供应决策。某些试剂、特殊化学品和进口设备的关税上调，增加了模板DNA製备、体外转录、酵素试剂和脂质赋形剂等关键投入品的总到岸成本。因此，采购团队和供应链经理正在采取多元化策略，例如签订长期合约、采用第二供应商协议以及评估区域供应商，以降低关税波动带来的风险。

详细的細項分析揭示了影响 mRNA 合成市场产品和需求的各项服务、流程、规模、技术、应用、用途和最终用户趋势。

透过严谨的市场细分，我们获得了深刻的洞察，揭示了不同的价值驱动因素，这些因素因服务、服务类型、製造工艺、规模、技术、应用、使用场景和最终用户群体而异，从而决定了mRNA合成能力的引入和商业化方式。按服务划分，市场活动主要集中在「加帽和加尾」、「In Silico设计」、「电脑辅助设计」、「修饰和优化」、「纯化和品管」、「储存和分发」以及「模板DNA製备」等领域，每个服务领域都需要专门的技能和品管系统。能够以整合方式提供这些服务的供应商可以缩短开发週期，而拥有先进专业知识的细分领域专家则有可能获得更高的利润。

区域战略观点：重点关注美洲、欧洲、中东和非洲以及亚太地区的製造地、法规环境和贸易相互依存关係。

区域趋势在美洲、欧洲、中东、非洲和亚太地区创造了不同的机会和营运考量，这些地区在创新能力、製造基础设施、法规结构和贸易伙伴关係方面存在差异。在美洲，强大的转化研究生态系统、丰富的创业投资和企业资本以及完善的合约研发生产机构（CDMO）网络，支持从概念到临床试验的快速进展。该地区还聚集了大量先进试剂供应商和专业分析服务提供商，为高品质生产提供支援。

关于主要企业、策略趋势、能力差异化因素以及塑造 mRNA 合成和製造生态系统的伙伴关係行为的关键竞争见解。

mRNA合成领域的企业竞争呈现出平台专业化、垂直整合和协作模式相结合的特点，旨在平衡上市速度和资本密集度。该领域的领导企业正投资于整合In Silico设计工具与稳健的製程开发和製剂技术的平台，从而减少交接流程，缩短从药物发现到符合GMP规范生产的周期。同时，其他企业则专注于先进脂质化学、高解析度纯化技术和专有酶试剂等领域的细分市场，成为更广泛生态系统中其他参与者的重要合作伙伴。

为产业领导者提供可操作的策略建议，以优化製造韧性、加快开发速度并增强全球供应链的敏捷性。

产业领导者应采取积极主动的措施，增强生产韧性，加快研发进程，并确保专案按计画进行。首先，应实现关键材料（如酵素、脂质和质体材料）筹资策略的多元化，并确保检验的二级供应商，以减少单点故障。其次，应投资模组化和一次性製程技术，以提高中试、临床和商业化生产宣传活动的柔软性，缩短切换时间并降低交叉污染的风险。第三，应优先加强先进的製剂和纯化能力，包括脂质奈米颗粒技术和高解析度RNA纯化技术的领先地位，以提高产品稳定性和临床疗效。

高度透明的调查方法，解释了用于获得关于 mRNA 合成的严格见解的数据来源、分析框架、专家检验和品管。

本分析所依据的研究采用了一种混合方法，结合了定性一手访谈、二手文献综述和技术检验，以确保结果的可靠性和实用性。主要资料来源是对产品开发和製造机构的製程开发科学家、供应链经理、法规事务专家和高阶主管进行的结构化访谈。这些对话揭示了实际存在的限制、策略重点和切实可行的解决方案，并以此为基础提出了可操作的建议。

经营团队总结了策略见解、营运重点和前瞻性考虑因素，供 mRNA 合成和製造领域的相关人员参考。

总之，mRNA合成和生产正进入一个以技术快速进步、商业模式不断演变以及对供应链韧性日益重视为特征的阶段。製剂技术、酵素学和数位设计方面的技术进步正在为提高治疗效果铺平道路，而不断变化的监管要求则对分析精度和製程控制提出了更高的要求。贸易政策和区域趋势的变化促使企业对采购和製造地进行策略性重新评估，使得供应链透明度和地域多角化成为营运策略的关键要素。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 mRNA 合成与製造市场：依服务分类

  • 封顶和尾部
  • 配方
  • In Silico设计
  • 修改和优化
  • 精炼/品管
  • 仓储/配送
  • 模板DNA製备

第九章 mRNA合成与製造市场：依服务类型划分

  • 客製化mRNA合成
    • 客户客製的mRNA订单
    • 客製化调查规范
  • 标准mRNA生产
    • 目录中列出的mRNA变体
    • 选择预製的mRNA

第十章 mRNA合成与製造市场：依製造流程划分

  • 先进的LNP製剂技术
  • 酶促加帽及其类似物
  • 基因工程和密码子优化
  • 体外移植
  • 质体DNA模板
  • 多聚腺苷酸化
  • RNA纯化技术

第十一章 依生产规模分類的mRNA合成与製造市场

  • 商业规模
  • 实验室规模
  • 中试规模

第十二章 mRNA 合成与製造市场：依技术划分

  • 体外合成
  • 内源性合成

第十三章 mRNA合成与製造市场：依应用领域划分

  • 治疗药物
    • 癌症
    • 感染疾病
    • 罕见疾病
  • 疫苗
    • 预防性疫苗
    • 治疗性疫苗

第十四章 mRNA合成与製造市场及其应用

  • 对人类而言
  • 兽用

第十五章 mRNA 合成与製造市场：依最终用户划分

  • 学术和研究机构
    • 政府研究机构
    • 大学研究所
  • 契约製造组织
  • 製药和生物技术公司

第十六章 mRNA 合成与製造市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十七章 mRNA 合成与製造市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十八章 mRNA 合成与製造市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十九章 美国mRNA合成与製造市场

第二十章 中国mRNA合成与製造市场

第21章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories Limited
  • Bio-Synthesis Inc.
  • Creative Biogene
  • Creative Biolabs
  • Croyez Bioscience Co., Ltd.
  • Danaher Corporation
  • FUJIFILM Wako Pure Chemical Corporation
  • Genewiz by Azenta Life Sciences
  • GenScript Biotech Corporation
  • Jena Bioscience GmbH by Enzo Biochem Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • New England Biolabs, Inc.
  • PackGene Biotech, Inc.
  • Promega Corporation
  • Samsung Biologics Co., Ltd.
  • Sartorius AG
  • ST Pharm
  • System Biosciences, LLC
  • Takara Bio Inc.
  • Telesis Bio Inc.
  • Thermo Fisher Scientific Inc.
  • TriLink BioTechnologies LLC by Maravai Intermediate Holdings, LLC
  • WuXi Biologics（Cayman）Inc
Product Code: MRR-6067B28994B1

The mRNA Synthesis & Manufacturing Market was valued at USD 2.96 billion in 2025 and is projected to grow to USD 3.23 billion in 2026, with a CAGR of 9.71%, reaching USD 5.67 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.96 billion
Estimated Year [2026] USD 3.23 billion
Forecast Year [2032] USD 5.67 billion
CAGR (%) 9.71%

An authoritative introduction to mRNA synthesis and manufacturing highlighting scientific foundations, commercialization pathways, regulatory advances, and supply chain complexities

Messenger RNA synthesis and manufacturing represent a convergence of molecular biology, engineering, regulatory science, and global supply chain management that together enable new therapeutic modalities and vaccine platforms. At its scientific core, mRNA manufacturing translates digital genetic designs into chemically and structurally optimized RNA constructs through defined processes such as template DNA preparation, in vitro transcription, capping and tailing, polyadenylation, purification, and formulation. Each stage demands specialized reagents, instrumentation, and process controls that reflect both the sensitivity of RNA molecules and the criticality of ensuring product quality for human and veterinary use.

Beyond the bench, commercialization pathways require alignment between research organizations, contract manufacturers, regulatory authorities, and distribution networks. The ecosystem is characterized by a mix of academic research groups that drive discovery, specialty suppliers that provide enzymes and lipids, contract development and manufacturing organizations that enable scale-up, and biopharmaceutical firms that integrate mRNA into therapeutic pipelines. This interplay influences timelines, capital intensity, and risk allocation as programs move from proof-of-concept to clinical testing and, eventually, to broad deployment.

Regulatory and quality expectations are evolving in parallel with technical advances. Regulators are emphasizing robust characterization of critical quality attributes, consistency of production, and demonstrated control of process-related impurities. Consequently, manufacturers are investing in analytical platforms and quality assurance frameworks to meet stringent release criteria and to support global regulatory filings. At the same time, supply chain robustness, cold chain logistics, and secure sourcing of critical raw materials remain practical constraints that shape program feasibility and strategic decisions. Taken together, these dimensions set the stage for an industry focused on innovation, operational excellence, and careful regulatory engagement.

Defining transformative shifts reshaping mRNA synthesis and manufacturing driven by platform technologies, delivery innovations, regulatory evolution, and strategic partnerships

The landscape of mRNA synthesis and manufacturing is undergoing transformative shifts driven by technological maturation, strategic partnerships, and shifting regulatory expectations. Advances in lipid nanoparticle design and alternative delivery modalities are extending the reach of mRNA therapeutics beyond traditional vaccine applications, enabling targeted delivery and improved tolerability. Concurrent improvements in enzymatic capping chemistry, cap analogues, and polyadenylation methods are increasing transcript stability and translational efficiency, thereby improving the therapeutic index of mRNA constructs.

Digital tools and in silico design platforms are accelerating sequence optimization and codon engineering, reducing iterative laboratory cycles and enabling more predictive design-to-manufacture pathways. This digitization is complemented by automation from bench to production, where modular and single-use systems allow faster campaign changeovers and reduce cross-contamination risk. The growing prominence of contract manufacturing organizations and strategic alliances is shifting capital burdens and creating flexible capacity models that support both bespoke clinical-scale programs and larger commercial runs.

Regulatory convergence and clearer guidance on quality attributes are prompting manufacturers to embed quality-by-design principles earlier in development, ensuring scalable processes are validated before full-scale commercial production. In parallel, supply chain resilience has become a strategic dimension; organizations are diversifying supplier bases for critical inputs such as nucleotides, enzymes, and lipid excipients while exploring regional production strategies to mitigate trade and logistics disruptions. Together, these shifts are reshaping competitive dynamics and opening opportunities for firms that can integrate advanced formulation science, robust quality systems, and agile manufacturing models.

Examining the cumulative effects of United States tariffs implemented in 2025 on mRNA synthesis supply chains, sourcing strategies, cost structures, and competitive positioning

The 2025 adjustments to United States tariff policy have introduced layered effects across the mRNA synthesis value chain, influencing sourcing, cost structures, and strategic supply decisions. Tariff escalation on certain reagents, specialty chemicals, and imported equipment has increased the total landed cost of critical inputs used in template DNA preparation, in vitro transcription, enzymatic reagents, and lipid excipients. As a consequence, procurement teams and supply chain managers are evaluating long-term contracts, second-source arrangements, and regional suppliers to reduce exposure to tariff-driven variability.

Operationally, tariffs are accelerating conversations around nearshoring and onshoring of key manufacturing activities. Organizations are assessing the trade-offs between higher local labor and infrastructure costs and the benefits of reduced border friction, faster lead times, and improved regulatory alignment. At the same time, manufacturers are revisiting inventory strategies and revising safety stock levels for high-risk components, balancing working capital impacts against the risk of production interruption.

Strategic responses also include renegotiation of supplier agreements to incorporate tariff sharing mechanisms, adoption of tariff classification optimization where appropriate, and investment in domestic capability for high-value intermediates. Furthermore, tariffs have catalyzed a renewed emphasis on supply chain transparency and traceability, prompting increased use of supplier audits and digital tools to monitor origin, movement, and compliance of raw materials. Collectively, these adaptations reflect how trade policy can materially influence operational resilience, supplier selection, and longer-term manufacturing footprints for complex biologics such as mRNA products.

In-depth segmentation insights revealing service, process, scale, technology, application, usage, and end-user dynamics that influence mRNA synthesis market offerings and demand

Insights derived from rigorous segmentation reveal distinct value drivers across services, service types, manufacturing processes, scales, technologies, applications, usage contexts, and end-user groups that define how mRNA synthesis capabilities are deployed and monetized. Based on Services, market activity clusters around Capping & Tailing, Formulation, In Silico Design, Modification & Optimization, Purification & Quality Control, Storage & Distribution, and Template DNA Preparation, with each service area requiring specialized skill sets and quality regimes. Providers offering an integrated suite of these services can shorten development timelines, whereas niche specialists may command premium margins for advanced capabilities.

Based on Service Type, distinctions between Custom mRNA Synthesis and Standard mRNA Production are material for positioning and client engagement. Custom mRNA Synthesis, including Client-Specific mRNA Orders and Tailored Research Specifications, caters to bespoke therapeutic programs and academic discovery projects where flexibility and deep technical support are essential. Standard mRNA Production, composed of Cataloged mRNA Variants and Off-the-Shelf mRNA Selections, aligns with reagent suppliers and platform offerings that prioritize reproducibility and immediate availability for screening or adjunct research applications.

Based on Manufacturing Process, competitive differentiation often stems from leadership in Advanced LNP Formulation Technology, Enzymatic Capping & Cap Analogues, Genetic Engineering & Codon Optimization, In Vitro Transcription, Plasmid DNA Template work, Polyadenylation, and RNA Purification Techniques. Mastery across these process elements reduces downstream risk and can accelerate clinical readiness. Based on Manufacturing Scale, providers operating across Commercial Scale, Lab Scale, and Pilot Scale can capture opportunity across development stages, but must maintain process transfer discipline to ensure performance parity when scaling.

Based on Technology, the split between In Vitro Synthesis and In Vivo Synthesis informs platform investments and regulatory approaches, with each route presenting unique quality and delivery considerations. Based on Application, differentiation emerges between Therapeutics and Vaccines, where Therapeutics encompasses Cancer, Infectious Diseases, and Rare Diseases and Vaccines comprises Prophylactic and Therapeutic Vaccines, each application area carrying distinct development timelines, clinical endpoints, and payer considerations. Based on Usage, Human Use and Veterinary Use markets require tailored regulatory pathways and manufacturing controls. Based on End-User, Academic & Research Institutes, Contract Manufacturing Organizations, and Pharmaceutical & Biotechnology Companies represent primary demand pockets, with Academic & Research Institutes further segmented into Government Research Bodies and University Laboratories, reflecting divergent procurement behaviors and quality expectations. Together, these segmentation lenses enable clearer targeting of capabilities, investment priorities, and commercial propositions for providers across the mRNA ecosystem.

Regional strategic perspectives across the Americas, Europe Middle East & Africa, and Asia-Pacific highlighting manufacturing hubs, regulatory climates, and trade interdependencies

Regional dynamics create differentiated opportunities and operational considerations across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct balances of innovation capacity, manufacturing infrastructure, regulatory frameworks, and trade linkages. In the Americas, strong translational research ecosystems, deep venture and corporate capital availability, and a robust network of contract development and manufacturing organizations support accelerated progression from concept to clinic. This region also benefits from a concentration of advanced reagent suppliers and specialized analytics providers that underpin high-quality production.

In Europe, Middle East & Africa, established pharmaceutical clusters, experienced regulatory bodies, and a tradition of collaboration between public research institutions and industry create an environment conducive to complex biologics development and cross-border partnerships. Regulatory harmonization efforts and a focus on manufacturing excellence make this region attractive for firms seeking high-standards production and access to diverse talent pools. The Asia-Pacific region combines large-scale manufacturing capabilities, growing R&D investment, and competitive operational cost structures. Rapid expansion of local supply chains, development of regional CDMOs, and governmental incentives for biotechnology investment are driving increased capacity for both development and commercial-scale manufacturing.

Across all regions, trade policies, logistics infrastructure, and workforce availability shape strategic decisions about where to locate specific manufacturing activities. Geopolitical considerations and tariff environments are prompting firms to consider hybrid and regionally diversified strategies to optimize responsiveness, regulatory alignment, and cost efficiency. Ultimately, a nuanced regional approach that aligns technical requirements with local strengths and policy realities will determine operational success in global mRNA supply networks.

Critical competitive intelligence on leading companies, strategic moves, capability differentiators, and partnership behaviors shaping mRNA synthesis and manufacturing ecosystems

Competitive behavior among companies operating in the mRNA synthesis sphere is characterized by a mix of platform specialization, vertical integration, and collaborative models that balance speed-to-market with capital intensity. Leaders in the field are investing in integrated platforms that combine in silico design tools with robust process development and formulation capabilities, thereby reducing handoffs and compressing timelines between discovery and GMP production. Other firms are concentrating on niche excellence, for example in advanced lipid chemistry, high-resolution purification technologies, or proprietary enzymatic reagents, thereby becoming critical partners for broader ecosystem participants.

Strategic moves commonly observed include technology licensing, co-development agreements, and alliances with specialized CDMOs to secure capacity and technical know-how. Mergers and acquisitions are being used selectively to acquire capability gaps quickly, while partnerships with academic centers support early access to novel sequences and translational insights. Investments in analytical development, process characterization, and digital manufacturing controls are differentiators that underpin regulatory filings and product consistency. Importantly, suppliers that can demonstrate validated supply chains for high-risk inputs and that offer contamination risk mitigation measures are increasingly preferred by developers who require secure sourcing for clinical and commercial programs.

Actionable strategic recommendations for industry leaders to optimize manufacturing resilience, accelerate development throughput, and strengthen global supply chain agility

Industry leaders should take a proactive stance to strengthen manufacturing resilience, accelerate development throughput, and protect program timelines. First, diversify sourcing strategies for critical inputs and establish validated second-source suppliers for enzymes, lipids, and plasmid materials to reduce single-point vulnerabilities. Second, invest in modular and single-use process technologies to increase flexibility across pilot, clinical, and commercial campaigns, enabling faster changeovers and lower cross-contamination risk. Third, prioritize advanced formulation and purification capabilities, including leadership in lipid nanoparticle engineering and high-resolution RNA purification, to improve product stability and clinical performance.

Additionally, embed quality-by-design practices earlier in development and expand analytical capabilities to support robust characterization and regulatory readiness. Strengthen partnerships with contract manufacturers and academic collaborators to access specialized expertise while managing capital exposure. Implement digital tools for in silico design, process analytics, and supply chain visibility to accelerate iteration cycles and to improve traceability. Finally, conduct scenario planning for trade and tariff changes, incorporating contractual hedges and regional manufacturing options to maintain continuity under shifting policy environments. These actions, taken together, will position organizations to respond more rapidly to scientific opportunities while mitigating operational and commercial risks.

Transparent research methodology explaining data sources, analytical frameworks, expert validation, and quality controls used to produce rigorous mRNA synthesis insights

The research underpinning this analysis employed a mixed-methods approach combining primary qualitative interviews, secondary literature review, and technical validation to ensure findings are robust and operationally relevant. Primary inputs included structured interviews with process development scientists, supply chain managers, regulatory affairs professionals, and senior executives across product developers and manufacturing organizations. These conversations were designed to elicit real-world constraints, strategic priorities, and practical mitigation tactics that inform actionable recommendations.

Secondary research included systematic review of peer-reviewed literature, publicly available regulatory guidance, patent filings, and technical white papers to map technology trajectories and identify validated process innovations. Where possible, triangulation methods were applied by cross-referencing interview insights with documented regulatory trends and supplier disclosures. Analytical frameworks focused on capability mapping, risk assessment, and scenario analysis, and findings were iteratively refined through an expert validation panel to reduce bias and strengthen applicability. Quality controls included source documentation, transparent assumption logs, and reproducible analytical steps to support traceability of conclusions.

Executive conclusion synthesizing strategic implications, operational priorities, and future-focused considerations for stakeholders in the mRNA synthesis and manufacturing domain

In conclusion, mRNA synthesis and manufacturing have entered a phase defined by rapid technical refinement, shifting commercial models, and heightened attention to supply chain resilience. Technological advances in formulation, enzymology, and digital design are creating pathways to broaden therapeutic impact, while evolving regulatory expectations are raising the bar for analytical rigor and process control. Trade policy shifts and regional dynamics are prompting strategic re-evaluation of sourcing and manufacturing footprints, making supply chain transparency and regional diversification essential components of operational strategy.

For stakeholders across the spectrum-developers, manufacturers, suppliers, and investors-the imperative is to align scientific ambition with pragmatic operational planning. Firms that integrate advanced process capabilities, adopt flexible manufacturing architectures, and engage in purposeful partnerships will be best positioned to translate mRNA innovation into dependable clinical and commercial outcomes. The emerging landscape rewards not just scientific ingenuity but also disciplined execution, strategic foresight, and resilient supply chain design.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. mRNA Synthesis & Manufacturing Market, by Services

  • 8.1. Capping & Tailing
  • 8.2. Formulation
  • 8.3. In Silico Design
  • 8.4. Modification & Optimization
  • 8.5. Purification & Quality Control
  • 8.6. Storage & Distribution
  • 8.7. Template DNA Preparation

9. mRNA Synthesis & Manufacturing Market, by Service Type

  • 9.1. Custom mRNA Synthesis
    • 9.1.1. Client-Specific mRNA Orders
    • 9.1.2. Tailored Research Specifications
  • 9.2. Standard mRNA Production
    • 9.2.1. Cataloged mRNA Variants
    • 9.2.2. Off-the-Shelf mRNA Selections

10. mRNA Synthesis & Manufacturing Market, by Manufacturing Process

  • 10.1. Advanced LNP Formulation Technology
  • 10.2. Enzymatic Capping & Cap Analogues
  • 10.3. Genetic Engineering & Codon Optimization
  • 10.4. In Vitro Transcription
  • 10.5. Plasmid DNA Template
  • 10.6. Polyadenylation
  • 10.7. RNA Purification Techniques

11. mRNA Synthesis & Manufacturing Market, by Manufacturing Scale

  • 11.1. Commercial Scale
  • 11.2. Lab Scale
  • 11.3. Pilot Scale

12. mRNA Synthesis & Manufacturing Market, by Technology

  • 12.1. In Vitro Synthesis
  • 12.2. In Vivo Synthesis

13. mRNA Synthesis & Manufacturing Market, by Application

  • 13.1. Therapeutics
    • 13.1.1. Cancer
    • 13.1.2. Infectious Diseases
    • 13.1.3. Rare Diseases
  • 13.2. Vaccines
    • 13.2.1. Prophylactic Vaccines
    • 13.2.2. Therapeutic Vaccines

14. mRNA Synthesis & Manufacturing Market, by Usage

  • 14.1. Human Use
  • 14.2. Veterinary Use

15. mRNA Synthesis & Manufacturing Market, by End-User

  • 15.1. Academic & Research Institutes
    • 15.1.1. Government Research Bodies
    • 15.1.2. University Laboratories
  • 15.2. Contract Manufacturing Organizations
  • 15.3. Pharmaceutical & Biotechnology Companies

16. mRNA Synthesis & Manufacturing Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. mRNA Synthesis & Manufacturing Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. mRNA Synthesis & Manufacturing Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States mRNA Synthesis & Manufacturing Market

20. China mRNA Synthesis & Manufacturing Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories Limited
  • 21.6. Bio-Synthesis Inc.
  • 21.7. Creative Biogene
  • 21.8. Creative Biolabs
  • 21.9. Croyez Bioscience Co., Ltd.
  • 21.10. Danaher Corporation
  • 21.11. FUJIFILM Wako Pure Chemical Corporation
  • 21.12. Genewiz by Azenta Life Sciences
  • 21.13. GenScript Biotech Corporation
  • 21.14. Jena Bioscience GmbH by Enzo Biochem Inc.
  • 21.15. Lonza Group Ltd.
  • 21.16. Merck KGaA
  • 21.17. New England Biolabs, Inc.
  • 21.18. PackGene Biotech, Inc.
  • 21.19. Promega Corporation
  • 21.20. Samsung Biologics Co., Ltd.
  • 21.21. Sartorius AG
  • 21.22. ST Pharm
  • 21.23. System Biosciences, LLC
  • 21.24. Takara Bio Inc.
  • 21.25. Telesis Bio Inc.
  • 21.26. Thermo Fisher Scientific Inc.
  • 21.27. TriLink BioTechnologies LLC by Maravai Intermediate Holdings, LLC
  • 21.28. WuXi Biologics (Cayman) Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CAPPING & TAILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CAPPING & TAILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CAPPING & TAILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN SILICO DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN SILICO DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN SILICO DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MODIFICATION & OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MODIFICATION & OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MODIFICATION & OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PURIFICATION & QUALITY CONTROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PURIFICATION & QUALITY CONTROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PURIFICATION & QUALITY CONTROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STORAGE & DISTRIBUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STORAGE & DISTRIBUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STORAGE & DISTRIBUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TEMPLATE DNA PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TEMPLATE DNA PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TEMPLATE DNA PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CLIENT-SPECIFIC MRNA ORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CLIENT-SPECIFIC MRNA ORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CLIENT-SPECIFIC MRNA ORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TAILORED RESEARCH SPECIFICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TAILORED RESEARCH SPECIFICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TAILORED RESEARCH SPECIFICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CATALOGED MRNA VARIANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CATALOGED MRNA VARIANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CATALOGED MRNA VARIANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY OFF-THE-SHELF MRNA SELECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY OFF-THE-SHELF MRNA SELECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY OFF-THE-SHELF MRNA SELECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ADVANCED LNP FORMULATION TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ADVANCED LNP FORMULATION TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ADVANCED LNP FORMULATION TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ENZYMATIC CAPPING & CAP ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ENZYMATIC CAPPING & CAP ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ENZYMATIC CAPPING & CAP ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GENETIC ENGINEERING & CODON OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GENETIC ENGINEERING & CODON OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GENETIC ENGINEERING & CODON OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VITRO TRANSCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VITRO TRANSCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VITRO TRANSCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PLASMID DNA TEMPLATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PLASMID DNA TEMPLATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PLASMID DNA TEMPLATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY POLYADENYLATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY POLYADENYLATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY POLYADENYLATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY RNA PURIFICATION TECHNIQUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY RNA PURIFICATION TECHNIQUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY RNA PURIFICATION TECHNIQUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COMMERCIAL SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COMMERCIAL SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY LAB SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY LAB SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY LAB SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PILOT SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PILOT SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PILOT SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VITRO SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VITRO SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VITRO SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VIVO SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VIVO SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VIVO SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PROPHYLACTIC VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PROPHYLACTIC VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PROPHYLACTIC VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY HUMAN USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY HUMAN USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY HUMAN USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VETERINARY USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VETERINARY USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VETERINARY USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GOVERNMENT RESEARCH BODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GOVERNMENT RESEARCH BODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GOVERNMENT RESEARCH BODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY UNIVERSITY LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY UNIVERSITY LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY UNIVERSITY LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 260. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 262. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 264. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 265. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 266. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 267. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 270. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 271. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 272. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 273. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-US